Download PDF
Eur J Pediatr Surg 2020; 30(05): 459-464
DOI: 10.1055/s-0039-1698764
Original Article

Can Free Carnitine or Bilirubin in Blood Be Used in Neonatal Screening for Biliary Atresia?

Zhenhua Gong 
1   Department of Pediatric Surgery, Children's Hospital affiliated to Shanghai Jiao Tong University, Shanghai, China
,
Yibo Wu
1   Department of Pediatric Surgery, Children's Hospital affiliated to Shanghai Jiao Tong University, Shanghai, China
,
Lulu Zheng
1   Department of Pediatric Surgery, Children's Hospital affiliated to Shanghai Jiao Tong University, Shanghai, China
,
Licai Chen
1   Department of Pediatric Surgery, Children's Hospital affiliated to Shanghai Jiao Tong University, Shanghai, China
,
Zhibzo Lv
1   Department of Pediatric Surgery, Children's Hospital affiliated to Shanghai Jiao Tong University, Shanghai, China
› Author Affiliations Funding This study was supported by the Science and Technology Commission of Shanghai Municipality (134119a4000) and the frontier technology research project of Shanghai Shenkang Hospital Development Center (SHDC12013124).
› Further Information
Also available at
    Permissions and Reprints

Abstract

Objective To investigate the efficiency of free carnitine, unconjugated bilirubin (UBIL), bilirubin monoglucuronide (BMG), and bilirubin diglucuronide (BDG) in dry blood spots (DBSs) measured using tandem mass spectrometry (MS/MS) for screening biliary atresia (BA).

Materials and Methods All the patients with BA, residing in Shanghai, were collected from four different children's hospitals in Shanghai from January 1, 2015, to June 30, 2017. UBILMS, BMG, BDG, and free carnitine were measured in the DBS samples of 48 patients with BA, 10,008 pediatric patients, and 52,862 newborns using MS/MS. Conjugated bilirubin was measured by MS/MS (CBMS) = BMG + BDG, and total bilirubin was measured by MS/MS (TBMS) = UBILMS + CBMS. Four hundred pediatric patients' direct bilirubin (DB) and total bilirubin (TB), measured by the clinical laboratory and MS/MS, were used as a control.

Results The total number of births at the registered permanent residences in Shanghai was 233,000; among them, the occurrence of BA was in 33 patients in 2 years. Therefore, the incidence of BA in Shanghai was 1:7,060. The ratio of DB/TB and CBMS/TBMS of most patients with BA was elevated gradually in the neonatal period and higher than the normal range after 1 month after birth. The area under the receiver operating characteristic curve of DB, DB/TB, CBMS/TBMS, CBMS, and free carnitine for predicting BA was 0.98, 0.95, 0.73, 0.57, and 0.92, respectively. Using the 95% percentile as a cutoff, the sensitivity of DB and free carnitine to predict BA was 100 and 85%, respectively, and the specificity was 52 and 85%, respectively.

Conclusion In free carnitine, DB, and CBMS/TBMS tests, blood concentrations are elevated in all infants with BA. However, they may not be elevated while they are newborns. These tests will result in high false negatives or positives. Thus, they should not be used as newborn screening tests for BA due to their lower sensitivity and specificity.

Keywords

biliary atresia - bilirubin - free carnitine - tandem mass spectrometry - neonatal screening

Note

The datasets analyzed during the current study are available from the corresponding author on reasonable request.




Publication History

Received: 05 May 2019

Accepted: 20 August 2019

Article published online:
10 October 2019

© 2020. Thieme. All rights reserved.

Georg Thieme Verlag KG
Stuttgart · New York

 

  • References

  • 1 Shneider BL, Moore J, Kerkar N. , et al; Childhood Liver Disease Research Network. Initial assessment of the infant with neonatal cholestasis-is this biliary atresia?. PLoS One 2017; 12 (05) e0176275
    CrossrefPubMedGoogle Scholar
  • 2 Kilgore A, Mack CL. Update on investigations pertaining to the pathogenesis of biliary atresia. Pediatr Surg Int 2017; 33 (12) 1233-1241
    CrossrefPubMedGoogle Scholar
  • 3 Hartley JL, Davenport M, Kelly DA. Biliary atresia. Lancet 2009; 374 (9702): 1704-1713
    CrossrefPubMedGoogle Scholar
  • 4 Nio M, Wada M, Sasaki H, Tanaka H. Effects of age at Kasai portoenterostomy on the surgical outcome: a review of the literature. Surg Today 2015; 45 (07) 813-818
    CrossrefPubMedGoogle Scholar
  • 5 Serinet MO, Wildhaber BE, Broué P. , et al. Impact of age at Kasai operation on its results in late childhood and adolescence: a rational basis for biliary atresia screening. Pediatrics 2009; 123 (05) 1280-1286
    CrossrefPubMedGoogle Scholar
  • 6 Matsui A. Screening for biliary atresia. Pediatr Surg Int 2017; 33 (12) 1305-1313
    CrossrefPubMedGoogle Scholar
  • 7 Lien TH, Chang MH, Wu JF. , et al; Taiwan Infant Stool Color Card Study Group. Effects of the infant stool color card screening program on 5-year outcome of biliary atresia in Taiwan. Hepatology 2011; 53 (01) 202-208
    CrossrefPubMedGoogle Scholar
  • 8 Gu YH, Yokoyama K, Mizuta K. , et al. Stool color card screening for early detection of biliary atresia and long-term native liver survival: a 19-year cohort study in Japan. J Pediatr 2015; 166 (04) 897-902
    CrossrefPubMedGoogle Scholar
  • 9 Mogul D, Zhou M, Intihar P, Schwarz K, Frick K. Cost-effective analysis of screening for biliary atresia with the stool color card. J Pediatr Gastroenterol Nutr 2015; 60 (01) 91-98
    CrossrefPubMedGoogle Scholar
  • 10 Goodhue C, Fenlon M, Wang KS. Newborn screening for biliary atresia in the United States. Pediatr Surg Int 2017; 33 (12) 1315-1318
    CrossrefPubMedGoogle Scholar
  • 11 Harpavat S, Garcia-Prats JA, Shneider BL. Newborn bilirubin screening for biliary atresia. N Engl J Med 2016; 375 (06) 605-606
    CrossrefPubMedGoogle Scholar
  • 12 Wang KS. Section on Surgery, Committee on Fetus and Newborn, Childhood Liver Disease Research Network. Newborn screening for biliary atresia. Pediatrics 2015; 136 (06) e1663-e1669
    CrossrefPubMedGoogle Scholar
  • 13 Bennett MJ. Newborn screening for metabolic diseases: saving children's lives and improving outcomes. Clin Biochem 2014; 47 (09) 693-694
    CrossrefPubMedGoogle Scholar
  • 14 Gong Z, Zheng L, Wang Y. , et al. Quantification of bilirubin from dry blood spots using tandem mass spectrometry. New J Chem 2018; 42: 19701-19706
    CrossrefPubMedGoogle Scholar
  • 15 Gong ZH, Tian GL, Wang YM. Blood spot carnitine and acylcarnitine in newborn to adolescence: measured by tandem mass spectrometry [in Chinese]. Zhonghua Er Ke Za Zhi 2010; 48 (12) 922-927
    PubMedGoogle Scholar
  • 16 Hopkins PC, Yazigi N, Nylund CM. Incidence of biliary atresia and timing of hepatoportoenterostomy in the United States. J Pediatr 2017; 187: 253-257
    CrossrefPubMedGoogle Scholar
  • 17 Wada H, Muraji T, Yokoi A. , et al. Insignificant seasonal and geographical variation in incidence of biliary atresia in Japan: a regional survey of over 20 years. J Pediatr Surg 2007; 42 (12) 2090-2092
    CrossrefPubMedGoogle Scholar
  • 18 Lee M, Chen SC, Yang HY, Huang JH, Yeung CY, Lee HC. Infant stool color card screening helps reduce the hospitalization rate and mortality of biliary atresia: a 14-year nationwide cohort study in Taiwan. Medicine (Baltimore) 2016; 95 (12) e3166
    CrossrefPubMedGoogle Scholar
  • 19 Watchko JF, Tiribelli C. Bilirubin-induced neurologic damage. N Engl J Med 2014; 370 (10) 979
    CrossrefPubMedGoogle Scholar
  • 20 Harpavat S, Finegold MJ, Karpen SJ. Patients with biliary atresia have elevated direct/conjugated bilirubin levels shortly after birth. Pediatrics 2011; 128 (06) e1428-e1433
    CrossrefPubMedGoogle Scholar
  • 21 Ye W, Rosenthal P, Magee JC, Whitington PF. Childhood Liver Disease Research and Education Network. Factors determining δ-bilirubin levels in infants with biliary atresia. J Pediatr Gastroenterol Nutr 2015; 60 (05) 659-663
    CrossrefPubMedGoogle Scholar
  • 22 Memon N, Weinberger BI, Hegyi T, Aleksunes LM. Inherited disorders of bilirubin clearance. Pediatr Res 2016; 79 (03) 378-386
    CrossrefPubMedGoogle Scholar
  • 23 Bhardwaj K, Locke T, Biringer A. , et al. Newborn bilirubin screening for preventing severe hyperbilirubinemia and bilirubin encephalopathy: a rapid review. Curr Pediatr Rev 2017; 13 (01) 67-90
    CrossrefPubMedGoogle Scholar
  • 24 Powell JE, Keffler S, Kelly DA, Green A. Population screening for neonatal liver disease: potential for a community-based programme. J Med Screen 2003; 10 (03) 112-116
    CrossrefPubMedGoogle Scholar
  • 25 Harpavat S, Ramraj R, Finegold MJ. , et al. Newborn direct or conjugated bilirubin measurements as a potential screen for biliary atresia. J Pediatr Gastroenterol Nutr 2016; 62 (06) 799-803
    CrossrefPubMedGoogle Scholar
  • 26 Madsen SS, Kvist N, Thorup J. Increased conjugated bilirubin is sufficient to initiate screening for biliary atresia. Dan Med J 2015; 62 (08) A5114
    PubMedGoogle Scholar
  • 27 Lam L, Musaad S, Kyle C, Mouat S. Utilization of reflex testing for direct bilirubin in the early recognition of biliary atresia. Clin Chem 2017; 63 (05) 973-979
    CrossrefPubMedGoogle Scholar
  • 28 Gong Z, Xu WJ, Tian GL, Zhang T, Lv Z. Neonatal intrahepatic cholestasis caused by citrin deficiency differentiated from biliary atresia. Eur J Pediatr Surg 2016; 26 (03) 255-259
    Article in Thieme ConnectPubMedGoogle Scholar